Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk

Stock Information for Q.E.P. Co., Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Q.E.P. Co., Inc.

Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners
Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results
Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting
Interpace Biosciences Announces Second Quarter 2025 Financial and Business Results
Interpace Biosciences Announces First Quarter 2025 Financial and Business Results
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results
PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan
OTC Markets Group Announces the 2025 OTCQX Best 50

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.